3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Oligodendroglioma
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Astrocytoma
1
Interventions
Temozolomide
69
Radiotherapy
30
Bevacizumab
24
Carboplatin
13
pembrolizumab
12
Radiation
11
Carmustine
8
Irinotecan
7
temsirolimus
6
Surgical Procedures, Operative
6
Radiosurgery
6
Erlotinib Hydrochloride
6
atezolizumab
5
Vorinostat
5
Sirolimus
5
Radiotherapy, Intensity-Modulated
5
Nivolumab
5
Lomustine
5
Everolimus
5
fludarabine
4
Radiotherapy, Conformal
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Aminolevulinic Acid
4
tipifarnib
3
Sorafenib
3
Paclitaxel
3
IL13-PE38
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Gemcitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioblastoma
×
picropodophyllin
×
Clear all
NCT01721577
2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2
Terminated
10 enrolled
8 charts